TY - JOUR
T1 - Targeting DDR2 for Treating Pancreatic Cancer
AU - Do, Chris T.P.
AU - Venkata, Prabhakar Pitta
AU - Prochnau, Jack Y.
AU - Singh, Deepika
AU - Timilsina, Santosh
AU - Subbarayalu, Panneerdoss
AU - Medina, Daisy
AU - Abdulsahib, Shahad
AU - Nirzhor, Saif
AU - Khan, Sajid
AU - Li, Guiming
AU - Polusani, Srikanth R.
AU - Zhou, Daohong
AU - Wang, Pei
AU - Chen, Yidong
AU - Vadlamudi, Ratna K.
AU - Hart, Matthew J.
AU - Amaradhi, Radhika
AU - McHardy, Stanton F.
AU - Rao, Manjeet K.
N1 - Publisher Copyright:
©2025 American Association for Cancer Research.
PY - 2025/10/1
Y1 - 2025/10/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with limited effective treatments, partly because of its complex tumor microenvironment. In this study, we report discoidin domain receptor 2 (DDR2), a receptor tyrosine kinase, as a critical protein that promotes PDAC growth and survival. Our results reveal that DDR2 is highly expressed and its expression correlates with the worst survival outcome in patients with PDAC. Using an unbiased high-throughput screen of small-molecule inhibitor libraries, we identified CIDD-8633, a novel inhibitor targeting DDR2. Our study suggests that CIDD-8633 interacts with DDR2 and inhibits DDR2-associated signaling. Importantly, in vivo studies demonstrate that CIDD-8633 effectively blocks PDAC tumor growth in preclinical mouse models. Additionally, combining CIDD-8633 with gemcitabine enhanced its efficacy synergistically. Mechanistically, CIDD-8633 treatment induces pro-apoptotic genes in PDAC cells. These findings position DDR2 as a promising therapeutic target and CIDD-8633 as a potential DDR2 inhibitor, offering new avenues for the treatment of PDAC.
AB - Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with limited effective treatments, partly because of its complex tumor microenvironment. In this study, we report discoidin domain receptor 2 (DDR2), a receptor tyrosine kinase, as a critical protein that promotes PDAC growth and survival. Our results reveal that DDR2 is highly expressed and its expression correlates with the worst survival outcome in patients with PDAC. Using an unbiased high-throughput screen of small-molecule inhibitor libraries, we identified CIDD-8633, a novel inhibitor targeting DDR2. Our study suggests that CIDD-8633 interacts with DDR2 and inhibits DDR2-associated signaling. Importantly, in vivo studies demonstrate that CIDD-8633 effectively blocks PDAC tumor growth in preclinical mouse models. Additionally, combining CIDD-8633 with gemcitabine enhanced its efficacy synergistically. Mechanistically, CIDD-8633 treatment induces pro-apoptotic genes in PDAC cells. These findings position DDR2 as a promising therapeutic target and CIDD-8633 as a potential DDR2 inhibitor, offering new avenues for the treatment of PDAC.
UR - https://www.scopus.com/pages/publications/105017717652
UR - https://www.scopus.com/pages/publications/105017717652#tab=citedBy
U2 - 10.1158/1535-7163.MCT-24-1226
DO - 10.1158/1535-7163.MCT-24-1226
M3 - Article
C2 - 40568905
AN - SCOPUS:105017717652
SN - 1535-7163
VL - 24
SP - 1570
EP - 1583
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 10
ER -